Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852823 | 0.87 | GAA (0.50) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL6633096 | 0.86 | DYRK1A (0.56) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL24251979 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL507628 | 0.80 | PPARA (0.49) | ALDH1A1MAPTPPARAGAADYRK1A | |
| SCHEMBL1748230 | 0.79 | PPARA (0.48) | SMN1; SMN2NPC1RAB9AALDH1A1PPARA | |
| SCHEMBL9808445 | 0.79 | CYP3A4 (0.51) | SMN1; SMN2NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL12298168 | 0.79 | PPARA (0.48) | ALDH1A1MAPTPPARAGAADYRK1A | |
| SCHEMBL1997208 | 0.79 | PPARA (0.48) | ALDH1A1MAPTPPARAGAADYRK1A | |
| SCHEMBL30602948 | 0.79 | PPARA (0.48) | ALDH1A1MAPTPPARAGAADYRK1A | |
| SCHEMBL15481046 | 0.78 | PPARA (0.48) | PPARADYRK1AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119569651-A | Carboxamide derivatives, pharmaceutical compositions containing the same, and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119522221-A | Cyanine dye, preparation method and application thereof, sample analysis method and analyzer | 深圳迈瑞生物医疗电子股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-117466834-A | Cyanine dye, its preparation method and use | 深圳迈瑞生物医疗电子股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2024017247-A1 | CYANINE DYE AND PREPARATION METHOD THEREFOR AND USE THEREOF, SAMPLE ANALYSIS METHOD, AND ANALYZER | 深圳迈瑞生物医疗电子股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| WO-2023076237-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| US-10640476-B2 | Bicyclic heteroaryl derivatives and preparation and uses thereof | XW LABORATORIES INC. (KY) | 2020-05-05 | — | — | US | disclosed |
| US-20170015671-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-01-19 | — | — | US | disclosed |
| US-20160031891-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2016-02-04 | — | — | US | disclosed |
| WO-2016019233-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-02-04 | — | — | WO | disclosed |
| CN-1049434-C | Aromatic amidine derivatives and pharmaceutically acceptable salts thereof | DAIICHI SEIYAKU CO (JP) | 2000-02-16 | — | — | CN | disclosed |
| US-5962695-A | ANTICOAGULANT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5866577-A | AN ANTICOAGULANT AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-02-02 | — | — | US | disclosed |
| CN-1168885-A | Process for prodn. of amidinoindole derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 1997-12-31 | — | — | CN | disclosed |
| CN-1168886-A | Process for production of amidinobenzofuran and amidionbenzothiophen derivatives and salt thereof | DAIICHI SEIYAKU CO (JP) | 1997-12-31 | — | — | CN | disclosed |
| US-5620991-A | ANTICOAGULANTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| US-5576343-A | ANTICOAGULANTS; BLOOD-COAGULATION FACTOR X INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0540051-B1 | Aromatic amidine derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 1996-04-03 | — | — | EP | disclosed |
| CN-1072677-A | Aromatic amidine derivative and salt thereof | DAIICHI SEIYAKU CO (JP) | 1993-06-02 | — | — | CN | disclosed |
| EP-0540051-A1 | Aromatic amidine derivatives and salts thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031891-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, SYK | SMN1; SMN2 4440/4885NPC1 4651/4885RAB9A 2340/4885 |
| US-20170015671-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, SYK | SMN1; SMN2 4440/4885NPC1 4651/4885RAB9A 2340/4885 |
| US-10640476-B2 | Bicyclic heteroaryl derivatives and preparation and uses thereof | GRIN2A, GRIN2C, GRIN3A | SMN1; SMN2 2428/4885NPC1 559/4885RAB9A 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.